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mass index (BMI) and fibromyalgia symptoms, there is uncertainty as to whether this
relationship is driven by physical factors, psychological factors, or both.
Objective: To assess these relationships in a clinical sample of patients with fibromyalgia.
Design: Cross-sectional study.
Setting: Tertiary care facility.
Patients: A total of 686 patients from an existing national fibromyalgia registry.
Methods: Patients completed a demographic form and self-report questionnaires
including the Fibromyalgia Impact QuestionnaireeRevised (FIQ-R), the Medical Outcomes
Study Short Forme36 (SF-36), the Brief Pain Inventory (BPI), and the 30-item Profile of
Mood States (30-item POMS).
Main Outcome Measurements: FIQ-R overall impact subscale.
Results: BMI was significantly correlated with fibromyalgia impact (P < .001). The rela-
tionship between BMI and fibromyalgia impact was almost fully accounted for by physical
factors and not by psychological factors.
Conclusions: Despite patient report that pain hinders physical activity, clinicians who
encounter patients with fibromyalgia, particularly patients with increased BMI, should be
cognizant of the need to invest time and resources to counsel patients on physical factors
(ie, physical activity) that could improve the patients’ symptom experience.
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Body mass index (BMI) above the normal range is a determinant both of more severe
symptoms and of worse health outcomes in patients with fibromyalgia [1-3]. Despite the
association between BMI and fibromyalgia symptoms, it is unclear whether this relationship
is driven by physical factors, psychological factors, or both [2,4-7]. This information is
important, as the prevalence of obesity in patients with fibromyalgia is high (47%-73%)
[1,5,7], and clinicians who encounter patients with fibromyalgia with an unhealthy BMI
need clear guidance on the most appropriate management for this group of patients.
Many factors, including decreased physical activity, stress, depression, anxiety, and
chronic sleep deprivation, have been linked with body weight in patients with fibromyalgia
[4,7]. For example, previous research has demonstrated that in fibromyalgia, being obese is
associated with greater pain severity, greater number of tender points, poorer sleep quality,
reduced physical strength and flexibility, and higher symptom burden when compared
to being of normal weight [2,5,6]. Also, women with fibromyalgia who are obese have
significantly higher levels of anxiety and depression, poorer quality of life, and poorer
physical performance than women with fibromyalgia who are not obese [6]. Despite this
body of research, no study to date has assessed the complex association between BMI,
physical, and psychological variables in the same model.
To evaluate complex relationships between variables, specific statistical techniques
such as mediation models that estimate direct relationships between variables and effects of802
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associations among BMI, physical factors, and psychological
factors in patients, we created a conceptual mediation model
(Figure 1). Specifically, we evaluated whether physical fac-
tors (physical activity and physical interference related to
pain) or psychological factors (depression and anxiety)
arbitrated this relationship. We hypothesized that (1) BMI
would be associated with overall fibromyalgia impact, and
(2) this relationship would be mediated by depression and
anxiety and by physical activity and physical interference
from pain.METHODS
Data for this analysis were derived from a sample of patients
with fibromyalgia (N ¼ 1303) who were randomly selected
from a national fibromyalgia registry [9] and were invited
to participate in a mailed survey. The overall response rate
to this survey was 65.5%. This study was approved by the
Mayo Clinic institutional review board.Participants
Only those respondents who met Fibromyalgia Research
Survey Criteria [10] were included in the present analyses
(N ¼ 686, 52.6% of the original sample). This is defined
as a widespread pain index (WPI) of 7 and symptom
severity (SS) 5 or a 3 WPI 6 and SS 9. In addition,
patients who were underweight (n ¼ 15) were excluded,
as factors responsible for their symptom profiles may be
different [4].Figure 1. Conceptual model of the association between body mass
derived putative mechanisms.Measures
Participants completed a questionnaire package that in-
cluded the Fibromyalgia Research Survey [10], the Fibro-
myalgia Impact QuestionnaireeRevised (FIQ-R) [11], the
Medical Outcomes Study Short Forme36 (SF-36) [12], the
Brief Pain Inventory (BPI) [13], and the 30-item Profile of
Mood States (30-item POMS) [14]. For these analyses, we
selected specific subscales (described below) to avoid overlap
between predictor and outcome variables. For example, the
FIQ symptom subscale was avoided, as it shared items with
both the BPI and POMS.
FIQ-R. The FIQ-R is a 21-item, validated, self-report mea-
sure used to assess symptom burden in patients with fi-
bromyalgia [11]. The FIQ-R yields 3 subscales (functioning,
overall impact of fibromyalgia, and symptom severity) and
a total summary score. Total scores range from 0 to 100,
and higher scores are indicative of greater symptom burden.
The FIQ-R has an internal consistency of 0.95 and is
commonly used in clinical trials of patients with fibromy-
algia [15-18]. For this analysis we selected the FIQ-R overall
impact subscale, which specifically assesses patients’ expe-
riences of how overwhelmed they were by fibromyalgia
and how having fibromyalgia influenced their ability to
accomplish goals. This subscale was selected because it
had no conceptual overlap with the predictor or mediator
variables.
SF-36. The SF-36 is a 36-item, validated self-report measure
that assesses quality of life and burden of disease [12]. It
yields 8 subscales (physical functioning, role-physical,
bodily pain, general health, vitality, social functioning,index (BMI) and fibromyalgia impact, including 4 theoretically
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(physical and mental). Component scores range from 0 to
100, and higher scores are indicative of better health. The
SF-36 has an internal consistency of 0.9 and has been used
in clinical trials of patients with fibromyalgia [19-21]. For
this analysis, we selected the SF-36 physical functioning
subscale, which assesses a patient’s ability to perform a va-
riety of tasks, including vigorous and moderate activities,
walking, bending/kneeling, and bathing/dressing.
BPI. The BPI is a 15-item, validated self-report measure of
chronic pain that assesses the presence of pain, pain severity,
and degree of pain interference [13]. The BPI yields 2 sub-
scales: pain severity and pain interference. Scores on the pain
severity and pain interference subscales range from 0 to 10,
and higher scores are indicative of greater pain. Internal
consistency for the pain severity score is 0.85 and for the
interference scale is 0.88. The BPI has been used in fibro-
myalgia clinical trials, and is considered an appropriate
measure of pain in fibromyalgia [16,22-25]. For this analysis
we selected the pain interference subscale, which assesses the
degree to which pain restricts or hinders physical activities
of daily living.
30-Item POMS. The 30-item POMS is a validated, self-
report measure of mood that yields 6 subscales (depression-
dejection, tension-anxiety, fatigue-inertia, vigor-activity,
anger-hostility, and confusion-bewilderment) and a total
mood disturbance score [14]. Scores on each subscale range
from 0 to 20, and higher scores are indicative of more severe
symptoms on all scales except for the vigor-activity scale,
where lower scores indicate more severe symptoms. The
30-item POMS has an internal consistency of 0.69 to 0.88
and has been used in patients with fibromyalgia [26-28].
For this analysis we selected the depression-dejection and
the tension-anxiety subscales to represent the symptoms of
depression and anxiety, respectively.Data Analyses
Data analyses were conducted using SPSS 19 (IBM Corp.,
Armonk, NY) and Amos 19 (Amos Development Corp.,
Crawfordville, FL). Amos 19 was used to estimate structural
equation models that tested model fit and total, direct, and
indirect effects. Our analyses used guidelines by Kline [29]
for model fit, and guidelines by Hayes [30] for assessing
direct and indirect effects. Generally accepted cutoffs for
model fit in structural equation models are 0.90 for the
comparative fit index (CFI) and 0.05 for the root mean
square error of approximation (RMSEA) [29]. SPSS was used
to estimate an initial Pearson correlation matrix, to examine
individual mechanisms, and to test the statistical significance
of each indirect effect using Hayes’ Process Macro [30].
Before each analysis, data were examined for adherence to
distributional assumptions and outliers. Statistical test results
were deemed significant at the P < .05 alpha level.RESULTS
Overall, 686 patients met inclusion criteria. On average, pa-
tients were 56.1 years (12.5 years) of age, had a BMI of 30.2
(7.3), were female (92.9%), and were of white ethnicity
(90.8%). Patients exhibited moderate to severe symptom
severity as evidenced by a total FIQ-R score of 55.5 (19.0;
range, 0-100). Means and standard deviations for variables
included in the mediation model are reported in Table 1.
Pearson correlations (Table 2) demonstrated expected but
modest associations between BMI and pain interference (r ¼
0.108, P ¼ .005), physical activity (r ¼ 0.280, P < .0001),
and overall fibromyalgia impact (r ¼ 0.138, P ¼ .0003)
(Table 1). BMI did not correlate with depression (r ¼ 0.050,
P ¼ .20) or anxiety (r ¼ 0.001, P ¼ .97) and hence were
not included in mediation analyses. The model tested the
mediating effects of pain interference and physical func-
tioning on the BMI-fibromyalgia impact association. Figure 2
provides the results of this model and shows the non-
standardized regression coefficients for each path. This path
diagram reveals that a 1-unit increase in BMI results in a small
(0.04) increase in pain interference, whereas the same 1-unit
increase in BMI results in a moderate (0.39) decrease in
physical activity scores. Likewise, a 1-unit increase in pain
interference scores results in a much larger (1.28) increase in
fibromyalgia impact scores, and a 1-unit increase in physical
activity scores results in a moderate (0.17) decrease in fi-
bromyalgia impact scores. There was a small, statistically
significant, indirect effect of BMI through pain interference
and physical functioning on fibromyalgia impact (B ¼ 0.11,
P ¼ .02). This indicates that a 1-unit increase in BMI acts,
through increased pain interference and decreased physical
activity, to result in an increase in fibromyalgia impact scores
of 0.11. There was no direct effect of BMI on fibromyalgia
impact, and removing the direct effect had no adverse effect
on model fit [Dc2 (1, N ¼ 657) ¼ 0.01, P ¼ .97], which
continued to show overall acceptable fit [c2 (1, N ¼ 657)
¼ 0.03, P ¼ .86; CFI ¼ 1.00; RMSEA ¼ 0.00]. Using the
Process Macro [30,31] for SPSS 19 (SPSS Inc., Chicago, IL), a
multiple mediation analysis allowed a test of each indirect
effect. Small indirect effects of BMI on fibromyalgia impact
acted through both pain interference (B ¼ 0.041, P < .05)
and physical functioning (B ¼ 0.067, P < .05), and these
indirect effects were equal in magnitude (B ¼ 0.03, P > .05).
Finally, a reverse mediation model was examined. In this
model, BMI acted as the mechanism of action for associations
between depression, anxiety, pain interference, and physical
functioning with fibromyalgia impact. This model did not
provide a good fit to the data [c2 (2, N ¼ 657) ¼ 408.19,
P < .001; CFI ¼ 0.45; RMSEA ¼ 0.56].DISCUSSION
Our results demonstrate that physical factors such as phys-
ical impairment related to pain and being physically active
Table 1. Demographic characteristics and descriptive statistics for questionnaires
Mean (SD) or n (%) Range Interpretation
Age, y 56.1 (12.5)
BMI 30.2 (7.3) <18.5 Underweight, 18.5 to <25.0 normal,
25.0 to <30 overweight, >30 obese
Gender
Male 49 (7.1)
Female 637 (92.9)
Race/ethnicity
White 623 (90.8)
Other 63 (9.2)
BPI
Pain interference 5.7 (2.3) 0-10 Higher scores indicate more severe pain
interference
SF-36
Physical functioning 33.4 (10.3) 0-100 Higher scores indicate better health
Physical component 30.1 (8.7) 0-100 Higher scores indicate better health
Mental component 40.2 (12.5) 0-100 Higher scores indicate better health
FIQ-R
Overall impact 11.0 (5.8) 0-20 Higher scores indicate more severe impact
of fibromyalgia on life and activities
Total 55.5 (19.0) 0-100 Higher scores indicate more severe impact
of fibromyalgia on life and activities
POMS
Depression-dejection 6.7 (5.1) 0-20 Higher scores indicate more severe symptoms
Tension-anxiety 7.2 (4.8) Higher scores indicate more severe symptoms
BMI ¼ body mass index; BPI ¼ Brief Pain Inventory; SF-36 ¼ Short Forme36; FIQ ¼ Fibromyalgia Impact Questionnaire; POMS ¼ Profile of Mood States.
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toms. Depression and anxiety were not correlated with BMI,
so they could not explain the relationship between BMI and
fibromyalgia impact. Our results are particularly noteworthy,
given that ours was a tertiary care population with higher
medical and psychological comorbidities, as indicated by SF-
36 scores that were significantly lower than those of the
general population in the United States [12].
Our findings indicate that as BMI increases, it becomes
more difficult for a patient to physically function and to be
active, which in turn influences the impact of fibromyalgia.
Although patients attempt to mitigate the effects of pain by
being less physically active, based on our results, lower
physical activity actually worsens the impact of the illness.
Although vigorous physical activity may not be feasible for
patients with chronic pain, physical activity can be increased
in multiple ways. For example, Fontaine and Clauw have
demonstrated that accumulating 30 minutes per day ofTable 2. Pearson correlations of body mass index and physical and
BMI
BPI Pain
Interference
SF-36 Physi
Functionin
BMI 1
BPI pain interference 0.108* 1
SF-36 physical functioning 0.280y 0.492y 1
FIQ overall impact 0.138y 0.642y 0.522y
POMS depression-dejection 0.050 0.481y 0.255y
POMS tension-anxiety 0.001 0.444y 0.168y
BMI ¼ body mass index; BPI ¼ Brief Pain Inventory; SF-36 ¼ Short Forme36; FIQ
*P < .01.
y
P < .001.lifestyle physical activities (such as walking, using the stairs,
gardening) was feasible for previously inactive patients with
fibromyalgia, and that this increased physical activity
decreased pain [32]. In addition, Levine et al demonstrated
that modifying simple lifestyle activities (for example,
walking and talking on the telephone instead of sitting,
having walking instead of sitting meetings in daily encoun-
ters, engaging in purposeful housekeeping, increasing stair
climbing) increased noneexercise activity thermogenesis
and decreased BMI [33]. Such activities may be pragmatic
alternatives to aerobic exercise, and may help patients with
fibromyalgia and high BMI to start moving.
Our study has several limitations. First, this is a cross-
sectional analysis, and correlations do not imply causality;
therefore, our results must be interpreted with caution. Only
a longitudinal study that assesses temporal relation-
ships of variables over time can shed light on causation. In
this study, in addition to correlations, we evaluated thepsychological factors
cal
g
FIQ Overall
Impact
POMS
Depression-Dejection
POMS
Tension-Anxiety
1
0.471y 1
0.413y 0.732y 1
¼ Fibromyalgia Impact Questionnaire; POMS ¼ Profile of Mood States.
Figure 2. Empirically derived model of body mass index (BMI), mechanisms, and fibromyalgia impact.
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This strengthens our understanding of potential mecha-
nisms. Second, the generalizability of our results is limited,
given our clinical sample consisting of patients with mod-
erate to severe symptoms. Our model will need to be vali-
dated in other clinical and community samples. Third,
although anxiety and depression were not significant medi-
ators in this model, it is important to point out that patients
with fibromyalgia have a high prevalence of comorbid mood
and anxiety disorders. These results were surprising, as
literature suggests an association between mood and obesity
[34,35] and will need further study. Fourth, given that
duration of symptoms was not assessed, we were unable to
determine whether this could have influenced symptom
burden. Fifth, because not all patients invited to participate
returned completed surveys, participation bias could limit
the generalizability of our findings. Finally, our sample size
was large, as is necessary to obtain reliable results from
structural equation modeling; however, large samples also
have copious statistical power and hence can detect small
associations that may not always be clinically meaningful.
The present findings offer theoretical support for influence
of BMI on fibromyalgia impact and putative mechanisms
of action, but the clinical utility and meaningfulness of
these modest interrelationships has yet to be determined in
applied clinical settings.CONCLUSIONS
To conclude, although a higher BMI increases pain and often
serves as a barrier to physical activity, transcending this
challenge even through the simplest of activities maytranslate to decreased pain. Obese and overweight patients
with other chronic conditions are routinely told that they
will help themselves if they move a little [36]. Our study is in
consonance with these reports. Clinicians who encounter
patients with fibromyalgia, particularly those with increased
BMI, should invest time and resources in counseling patients
to increase physical activity.ACKNOWLEDGMENTS
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